Avapritinib
Avapritinib 300 mg
300 mg · ITT
3L or later GIST (n = 240)
Comparator: regorafenib 160 mg
progression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055
VOYAGER · NCT03465722
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
GIST pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
7 arms have a reported figure in this set.
Avapritinib 300 mg
300 mg · ITT
3L or later GIST (n = 240)
Comparator: regorafenib 160 mg
progression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055
VOYAGER · NCT03465722
Bezuclastinib 600 mg + sunitinib 37.5 mg
600 mg + 37.5 mg · ITT
GIST after imatinib (n = 204)
Comparator: sunitinib 37.5 mg
progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025
PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update
Peak · NCT05208047
Imatinib 400 mg for 12 months
400 mg · ITT
resected primary GIST 3 cm or more
Comparator: placebo
recurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 months
recurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months
Adjuvant Study 1 (ACOSOG Z9001) · NCT00041197
Imatinib 400 mg for 36 months
400 mg · ITT
resected high-risk KIT positive GIST
Comparator: imatinib for 12 months
recurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 months
overall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months
Adjuvant Study 2 (SSG XVIII) · NCT00116935
Regorafenib 160 mg, 3 weeks on 1 off
160 mg · ITT
GIST after imatinib and sunitinib
Comparator: placebo
progression-free survival hazard ratio vs placebo: 0.27 HR, primary analysis
GRID · NCT01271712
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib, sunitinib and regorafenib
Comparator: placebo
progression-free survival hazard ratio vs placebo: 0.15 HR, primary analysis
INVICTUS · NCT03353753
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib (ITT n = 226)
Comparator: sunitinib 50 mg 4/2
progression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significant
INTRIGUE · NCT03673501
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.